Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danielle Kim

Internal Medicine Bloomington, IL Doctor of Osteopathy

NPI 1770592487 CMS profile 171068

1401 Eastland Dr, Bloomington, IL 61701

Open in the dashboard

General payments

$4,605

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Kim of Bloomington, IL is reported in the CMS Open Payments database as having received $4,605 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,215 67
2024 General $1,449 90
2023 General $538 32
2022 General $777 37
2021 General $159 13
2020 General $220 14
2019 General $247 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Kim
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Danielle Kim were reported at $1,215. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Danielle Kim Internal Medicine median Middle half National median
2019 $247 $159 $48–$570 $163
2020 $220 $119 $33–$402 $114
2021 $159 $135 $37–$521 $132
2022 $777 $141 $42–$496 $149
2023 $538 $149 $45–$519 $160
2024 $1,449 $154 $47–$537 $164
2025 $1,215 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $913 62 payments
  2. Pfizer Inc. $667 42 payments
  3. AstraZeneca Pharmaceuticals LP $407 24 payments
  4. Novo Nordisk Inc $310 23 payments
  5. Lilly USA, LLC $296 18 payments
  6. Merit Medical Systems Inc $218 1 payment
  7. Bayer HealthCare Pharmaceuticals Inc. $218 14 payments
  8. Astellas Pharma US Inc $148 8 payments
  9. Novartis Pharmaceuticals Corporation $140 8 payments
  10. Dexcom, Inc. $139 8 payments
  11. Other $1,149 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,605 271 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $454 27 payments
  2. UBRELVY $419 26 payments
  3. ZAVZPRET $305 17 payments
  4. VRAYLAR $283 20 payments
  5. Savi SCOUT $218 1 payment
  6. SAVI Brachy $218 1 payment
  7. Kerendia $218 14 payments
  8. AIRSUPRA $197 10 payments
  9. QULIPTA $197 10 payments
  10. BREZTRI $188 10 payments
  11. Other $3,708 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

6,516

Median for Internal Medicine: 777

Drug cost

$506,225

Median for Internal Medicine: $73,373

Branded share of claims

17.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 63 $91,644
Jardiance Empagliflozin Brand 59 $78,192
Mounjaro Tirzepatide Brand 43 $64,355
Eliquis Apixaban Brand 61 $59,277
Xarelto Rivaroxaban Brand 24 $35,092
Breo Ellipta Fluticasone/Vilanterol Brand 39 $24,805
Nurtec Odt Rimegepant Sulfate Brand 12 $23,829
Victoza 3-Pak Liraglutide Brand 11 $17,316
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $12,553
Myrbetriq Mirabegron Brand 13 $7,084

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$157,970

Of which drugs: $16,047

Medicare patients

311

Average age 74

Services billed

5,205

261 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 47%
Osteoporosis 28%
Ischemic heart disease 20%
Diabetes 19%
Chronic kidney disease 16%
Cancer 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 85 85 $6,873
Sarscv2 vac 30mcg trs-suc im 91320 Office 34 37 $5,354
Pcv20 vaccine im 90677 Office 13 13 $3,751

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $164
$164 — —
JARDIANCE
  • Lilly USA, LLC $80
  • Boehringer Ingelheim Pharmaceuticals, Inc. $29
$109 59 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $107
$107 — —
NURTEC ODT
  • PFIZER INC. $97
$97 12 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record